Build the U.S. market around capability gaps, not generic MedTech lists.
The highest-fit account has valuable clinical or scientific IP, a real path to market, and a software/regulatory gap MedDev Solutions can solve faster than the company can build internally.
70% focus where MedDev is most differentiated.
Start narrow enough to learn quickly, then widen the market without losing the buying logic.
Early-stage U.S. companies with scientific or clinical IP but incomplete regulated-software capability.
- Seed through Series B
- Often 10-100 employees
- Python / MATLAB / TensorFlow / PyTorch heavy
- Moving from research or validation into a clinical product
- Missing IEC 62304, SQA/V&V, QMS or medical cyber depth
Digital health platforms and device manufacturers with a defined remediation, modernization or capacity problem.
- Legacy software gaps
- EU MDR / FDA remediation
- Connected-device cybersecurity
- Overflow V&V/SQA
- NPS validation or QMS buildout
Start where target-company density is highest.
The first research run will cover the U.S. broadly, with extra weight on major MedTech and digital-health clusters.
Score fit before spending selling time.
Illustrative scoring for the research lab. I would reweight it after reviewing MedDev Solutions' actual wins, losses and deal sizes.
One schema across 1,000+ accounts.
That lets us compare companies without turning account research into one-off notes.
segment · funding · employee count · HQ · product
Python/MATLAB · cloud · device software · ALM/QMS clues
RUO · clinical · 510(k) · De Novo · PMA · MDR
CTO · VP R&D · RA/QA · founder · software lead
funding · filing · audit · hiring · partnership · launch